Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

U.S. stock futures advance, U.S.-listed shares of Novo Nordisk fall on news its CEO is stepping down, and Charter ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

Stocks closed solidly higher on Friday, pushing major indexes to big weekly gains for the third time in the last four weeks.

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival ...

We came across a bullish thesis on Novo Nordisk A/S (NVO ... payer alignment are expected to redirect patient volumes back toward branded Wegovy. International expansion is accelerating ...